## Correction





## Correction: Optimal Attenuation of Experimental Autoimmune Encephalomyelitis by Intravenous Immunoglobulin Requires an Intact Interleukin-11 Receptor

## The PLOS ONE Staff

There are errors in the author affiliations. The affiliations should appear as shown here:

Carlyn A. Figueiredo<sup>1,2</sup>, Paulina C. Drohomyrecky<sup>4</sup>, Stephen D. S. McCarthy<sup>1,2</sup>, Danila Leontyev<sup>1</sup>, Xue-Zhong Ma<sup>1</sup>, Donald R. Branch<sup>1,2,3\*5</sup>, Shannon E. Dunn<sup>3,4,5\*5</sup>

- 1 Centre for Innovation, Canadian Blood Services, 67 College Toronto, Toronto, Ontario, Canada,
- 2 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada,
- 3 Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada,
- 4 Department of Immunology, University of Toronto, Toronto, Ontario, Canada,
- 5 Women's College Research Institute, Toronto, Ontario, Canada
- \* Email: don.branch@utoronto.ca (DRB); sdunn@uhnresearch.ca (SED)
  - **9** These authors contributed equally to this work.

## Reference

 Figueiredo CA, Drohomyrecky PC, McCarthy SDS, Leontyev D, Ma X-Z, et al. (2014) Optimal Attenuation of Experimental Autoimmune Encephalomyelitis by Intravenous Immunoglobulin Requires an Intact Interleukin-11 Receptor. PLoS ONE 9(7): e101947. doi:10.1371/journal.pone.0101947

**Citation:** The *PLOS ONE* Staff (2014) Correction: Optimal Attenuation of Experimental Autoimmune Encephalomyelitis by Intravenous Immunoglobulin Requires an Intact Interleukin-11 Receptor. PLoS ONE 9(11): e113001. doi:10.1371/journal.pone.0113001

Published November 4, 2014

**Copyright:** © 2014 The *PLOS ONE* Staff. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.